Clinicopathological features and prognosis of patients with gastric neuroendocrine tumors: A population‐based study

Abstract

BackgroundDespite its rarity, studies have shown the incidence of gastric neuroendocrine tumors (G‐NETs) is increasing. This study investigated the risk factors affecting the survival of G‐NETs patients and their prognosis over time.MethodA retrospective analysis of 506 G‐NETs patients who underwent surgery for nonmetastatic disease from the Surveillance, Epidemiology and End Result database from 1988 to 2011 was conducted. Multivariate Cox regression analyses identified the prognostic factors affecting overall survival (OS) and disease‐specific survival (DSS). Three‐year conditional survival (COS3 and CDS3) estimates at “x” year after treatment were calculated as follows: COS3 = OS(x + 3)/OS(x) and CDS3 = DSS(x + 3)/DSS(x).ResultsThe 1‐, 3‐, and 5‐year OS rates of all patients after surgery were 90.2%, 77.3%, and 68.8%, respectively. The 1‐, 3‐, and 5‐year DSS rates after surgery were 93.9%, 84.5%, and 80.9%, respectively. In the multivariate analysis, age, tumor grade, and T stage were independent prognostic factors of OS and DSS (all P < 0.05). With 1‐, 3‐, and 5‐year survivorship, the COS3 improved by +5.2 (82.2%), +7.2 (84.4%), and +8.5 (85.5%), respectively, and the CDS3 improved by +4.4 (89.4%), +9.1 (94.1%), and +12.5 (97.5%), respectively. Notably, the CDS3 improved dramatically among patients with advanced stage disease (eg, N0 stage: 93.0%‐98.9%, Δ5.9% vs N1 stage: 52.0%‐95.7%, Δ43.7%).ConclusionFor G‐NETs patients, age, tumor grade, T stage, and N stage were the clinicopathological factors significantly associated with prognosis. There were excellent outcomes for most G‐NETs patients, with a CDS3 of greater than 90% across all independent prognostic factors after 5 years of survival.

Trends of incidence and prognosis of gastric neuroendocrine neoplasms: a study based on SEER and our multicenter research

“…GNENs were an orphan disease and accounted for 6.9% of all the GEP-NENs, representing 0.3-1.8% of all gastric malignancies [17][18][19]. Based on the up-to-date SEER database, our study revealed that the incidence of GNENs has increased gradually in the past 4 decades, consisting with the previous study [1,2,17].…”

Clinicopathological characteristics and prognosis of 232 patients with poorly differentiated gastric neuroendocrine neoplasms

“…PDGNENs are rare tumors that are highly malignant, accounting for 6.9% of gastroenteropancreatic neuroendocrine tumors and 0.3%-1.8% of all malignant gastric tumors[ 9 , 10 ]. According to the Korean literature, PDGNENs account for 2.84% of all NENs and 40% of G-NENs[ 11 ].…”

Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States

“…On the other hand, given the rarity and indolent biological behavior of GEP-NETs, most studies on GEP-NETs are based on a small (or very small) number of cases in single institutions. [8][9][10][11] In addition, population-based studies have never specifically targeted GEP-NETs but rather only addressed the issue of NETs in a single gastrointestinal tract site (eg, stomach, 12 colon, 13 small intestine, 14 appendix, 15 or pancreas 16 ). Therefore, in this study, we performed a population-based study using the information in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program to systematically analyze the epidemiologic, clinical, and prognostic characteristics of GEP-NETs.…”